Drug data last refreshed Yesterday
DIASTAT (diazepam) is a benzodiazepine rectal gel approved in 1997 for the acute treatment of seizures and epilepsy management. It works by enhancing GABA's inhibitory effects on CNS neurons, reducing excessive depolarization that triggers seizure activity. The rectal route enables rapid, non-invasive administration in emergency settings where IV access is unavailable.
Product is in LOE phase with 60% competitive pressure, indicating team contraction and focus on managed decline rather than growth initiatives.
Benzodiazepine
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Worked on DIASTAT at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDIASTAT roles offer limited growth trajectory given LOE status and zero linked job openings, making this a career defensive position rather than an advancement opportunity. Work on this product primarily involves protecting market share against competitors and managing the product's decline cycle, with heavy emphasis on safety management given the benzodiazepine abuse signal.